Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily H Jung

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
JAMA Ophthalmology|February 2, 2023
Two-Year Outcomes After Variable Duration of Drug Cessation in Patients With Maculopathy Associated With Pentosan Polysulfate UseEmily H Jung, Aaron Lindeke-Myers, Nieraj Jain
Journal of General Internal Medicine|January 4, 2020
Novelty of Active Ingredients in High-Cost Brand-Name DrugsEmily H Jung, Ameet Sarpatwari, Aaron S Kesselheim
Circulation. Cardiovascular Quality and Outcomes|December 6, 2022
Getting Cost Discussions Right: Nudging Patients to Avoid Cognitive PitfallsBirju R Rao, Emily H Jung, Neal W Dickert
Ophthalmic Genetics|September 11, 2024
A novel large multi-gene deletion in syndromic choroideremiaEmily H Jung, Anna Duemler, Alessandro Iannaccone, et al.
Journal of General Internal Medicine|December 7, 2019
Correction to: FDA and EMA Biosimilar ApprovalsEmily H Jung, Ameet Sarpatwari, Aaron S Kesselheim, et al.
Journal of General Internal Medicine|October 23, 2019
FDA and EMA Biosimilar ApprovalsEmily H Jung, Ameet Sarpatwari, Aaron S Kesselheim, et al.
Pediatric Dermatology|January 19, 2023
Immunoglobulin A vasculitis presenting as bilateral upper eyelid erythema: A case report and review of literatureEmily H Jung, Sarah A Avila, Samantha Nastasi, et al.
JAMA Network Open|August 31, 2019
Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled AnalysisBishal Gyawali, Frazer A Tessema, Emily H Jung, et al.
JAMA Oncology|December 19, 2024
Government Funding for the Development of EnzalutamideBishal Gyawali, Emily H Jung, Helen Mooney, et al.
Plos Medicine|October 22, 2019
Desmopressin and the risk of hyponatremia: A population-based cohort studyMichael Fralick, Sebastian Schneeweiss, Christopher J D Wallis, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
JAMA Ophthalmology|February 2, 2023
Two-Year Outcomes After Variable Duration of Drug Cessation in Patients With Maculopathy Associated With Pentosan Polysulfate UseEmily H Jung, Aaron Lindeke-Myers, Nieraj Jain
Journal of General Internal Medicine|January 4, 2020
Novelty of Active Ingredients in High-Cost Brand-Name DrugsEmily H Jung, Ameet Sarpatwari, Aaron S Kesselheim
Circulation. Cardiovascular Quality and Outcomes|December 6, 2022
Getting Cost Discussions Right: Nudging Patients to Avoid Cognitive PitfallsBirju R Rao, Emily H Jung, Neal W Dickert
Ophthalmic Genetics|September 11, 2024
A novel large multi-gene deletion in syndromic choroideremiaEmily H Jung, Anna Duemler, Alessandro Iannaccone, et al.
Journal of General Internal Medicine|December 7, 2019
Correction to: FDA and EMA Biosimilar ApprovalsEmily H Jung, Ameet Sarpatwari, Aaron S Kesselheim, et al.
Journal of General Internal Medicine|October 23, 2019
FDA and EMA Biosimilar ApprovalsEmily H Jung, Ameet Sarpatwari, Aaron S Kesselheim, et al.
Pediatric Dermatology|January 19, 2023
Immunoglobulin A vasculitis presenting as bilateral upper eyelid erythema: A case report and review of literatureEmily H Jung, Sarah A Avila, Samantha Nastasi, et al.
JAMA Network Open|August 31, 2019
Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled AnalysisBishal Gyawali, Frazer A Tessema, Emily H Jung, et al.
JAMA Oncology|December 19, 2024
Government Funding for the Development of EnzalutamideBishal Gyawali, Emily H Jung, Helen Mooney, et al.
Plos Medicine|October 22, 2019
Desmopressin and the risk of hyponatremia: A population-based cohort studyMichael Fralick, Sebastian Schneeweiss, Christopher J D Wallis, et al.
Pageof 3